Holen Sie sich die Stockscreener-App
521.04
1.07%
5.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$515.55
Offen:
$520
24-Stunden-Volumen:
148.08K
Relative Volume:
0.10
Marktkapitalisierung:
$131.97B
Einnahmen:
$12.34B
Nettoeinkommen (Verlust:
$4.34B
KGV:
30.89
EPS:
16.8685
Netto-Cashflow:
$3.71B
1W Leistung:
-1.62%
1M Leistung:
+7.30%
6M Leistung:
+10.80%
1J Leistung:
+33.65%
1-Tages-Spanne:
$517.34
$524.21
1-Wochen-Bereich:
$502.29
$531.22
52-Wochen-Spanne:
$374.17
$546.17
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
520.66 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
811.46 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.58 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.46 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
367.13 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
UNIVEST FINANCIAL Corp Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Perigon Wealth Management LLC Takes $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Citizens Financial Group Inc. RI Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cornerstone Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
6,857 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Commerzbank Aktiengesellschaft FI - MarketBeat
Deutsche Bank AG Invests $784.39 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
BlackRock Inc. Invests $11.98 Billion in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC - MarketBeat
Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Nippon Life Global Investors Americas Inc. Makes New $18.99 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC - MarketBeat
TFR Capital LLC. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
125,970 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by ABN AMRO Bank N.V. - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) stock in focus as gene therapy sales climb - Kalkine Media
Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Yahoo Finance
Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near? - Yahoo Finance
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - The Motley Fool
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance - Yahoo Finance
Vertex-Crinetics pharma merger cleared in US, Germany, Austria, Australia - mlex.com
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade) - Seeking Alpha
Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances - Investing.com
Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones - Stock Titan
Vertex Pharmaceuticals Inc (VRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says - marketscreener.com
Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
RBC Capital reiterates Vertex stock rating on pipeline outlook By Investing.com - Investing.com Canada
Scotiabank Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - The Globe and Mail
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $633 - Moomoo
Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60% - Fierce Biotech
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Bernstein reiterates Vertex stock rating on cystic fibrosis outlook By Investing.com - Investing.com Canada
Bernstein reiterates Vertex stock rating on cystic fibrosis outlook - Investing.com
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - Yahoo Finance
Vertex Pharma stock added to BofA US 1 list of top ideas - Investing.com Nigeria
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Handelsbanken Fonder AB - MarketBeat
Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating - marketscreener.com
Vertex Pharmaceuticals Faces New Competitive Threats - Intellectia AI
VERTEX PHARMACEUTICALS INCORPORATED : JEFFERIES RAISES TARGET PRICE TO $633 FROM $610 - Bitget
Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers - webull.com
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vertex Pharmaceuticals Inc-Aktie (VRTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
0.70%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):